Defunct Company
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
111
NCT02675946
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 29, 2016
Completion: Mar 31, 2023
NCT03507998
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Start: Jun 17, 2017
Completion: Apr 1, 2021